Galapagos NV (NASDAQ: GLPG) and Intrexon Corporation (NYSE:XON) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Analyst Ratings

This is a summary of current ratings for Galapagos NV and Intrexon Corporation, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galapagos NV 0 1 7 0 2.88
Intrexon Corporation 0 1 4 0 2.80

Galapagos NV presently has a consensus price target of $104.60, indicating a potential upside of 13.09%. Intrexon Corporation has a consensus price target of $41.00, indicating a potential upside of 107.81%. Given Intrexon Corporation’s higher possible upside, analysts plainly believe Intrexon Corporation is more favorable than Galapagos NV.

Valuation & Earnings

This table compares Galapagos NV and Intrexon Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Galapagos NV N/A N/A N/A ($0.65) -142.29
Intrexon Corporation $202.92 million 11.72 -$99.62 million ($1.03) -19.16

Galapagos NV has higher revenue, but lower earnings than Intrexon Corporation. Galapagos NV is trading at a lower price-to-earnings ratio than Intrexon Corporation, indicating that it is currently the more affordable of the two stocks.


This table compares Galapagos NV and Intrexon Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galapagos NV -16.29% -3.42% -2.46%
Intrexon Corporation -60.63% -19.08% -11.53%

Insider and Institutional Ownership

23.6% of Galapagos NV shares are owned by institutional investors. Comparatively, 82.3% of Intrexon Corporation shares are owned by institutional investors. 2.9% of Galapagos NV shares are owned by insiders. Comparatively, 55.1% of Intrexon Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Galapagos NV has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Intrexon Corporation has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.


Galapagos NV beats Intrexon Corporation on 7 of the 11 factors compared between the two stocks.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.